CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

anti-CD19 CAR-T cell therapy (allogeneic, CRISPR-edited) · Caribou Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy, covering 2025-09-19 to 2025-09-19. Get the full timeline:

Most recent: Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) [Phase 1]

See pricing